ID   LoVo-92
AC   CVCL_5237
SY   Lovo-92; Lovo 92; Lovo92
DR   BTO; BTO:0004146
DR   cancercelllines; CVCL_5237
DR   GEO; GSM503149
DR   Progenetix; CVCL_5237
DR   Wikidata; Q54902900
RX   PubMed=8632910;
RX   PubMed=9989828;
RX   PubMed=17339891;
RX   PubMed=18600534;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0399 ! LoVo
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=8632910;
RA   Pocard M., Chevillard S., Villaudy J., Poupon M.-F., Dutrillaux B.,
RA   Remvikos Y.;
RT   "Different p53 mutations produce distinct effects on the ability of
RT   colon carcinoma cells to become blocked at the G1/S boundary after
RT   irradiation.";
RL   Oncogene 12:875-882(1996).
//
RX   PubMed=9989828; DOI=10.1038/sj.onc.1202336;
RA   Soulie P., Poupon M.-F., Remvikos Y., Dutrillaux B., Muleris M.;
RT   "Distinct chromosomal alterations associated with TP53 status of LoVo
RT   cells under PALA selective pressure: a parallel with cytogenetic
RT   pathways of colorectal cancers.";
RL   Oncogene 18:775-781(1999).
//
RX   PubMed=17339891; DOI=10.1038/sj.bjc.6603639;
RA   Giovannetti E., Backus H.H.J., Wouters D., Ferreira C.G.,
RA   van Houten V.M.M., Brakenhoff R.H., Poupon M.-F., Azzarello A.,
RA   Pinedo H.M., Peters G.J.;
RT   "Changes in the status of p53 affect drug sensitivity to thymidylate
RT   synthase (TS) inhibitors by altering TS levels.";
RL   Br. J. Cancer 96:769-775(2007).
//
RX   PubMed=18600534; DOI=10.1080/15257770802145512;
RA   Giovannetti E., Backus H.H.J., Wouters D., Peters G.J.;
RT   "Functional inactivity and mutations of p53 differentially affect
RT   sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate
RT   synthase (TS) by altering TS levels in colorectal cancer cells.";
RL   Nucleosides Nucleotides Nucleic Acids 27:740-745(2008).
//